Abstract: The invention relates to a product for the release of highly lipophilic physiologically active substances, comprising a core and a coating on top of the core, the coating comprising one or more highly lipophilic physiologically active substances, one or more water-soluble film-forming agents and, relative to the weight of all components, not more than 20 wt % of other auxiliary substances.

Abstract: The invention relates to a solid dosage form that comprises a matrix with one or more highly lipophilic physiologically active substances, one or more water-soluble binders and, relative to the weight of all components, not more than 20 wt % of other auxiliary substances, wherein a physiologically active substance being highly lipophilic if it has a log P of 4 or more.

Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune diseases, chronic inflammatory diseases and inflammatory conditions in connection with infections, including cytokine release syndrome (CRS). Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from conditions as referred to above.

Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from COVID-19, a disease caused by the coronavirus SARS-Cov-2. Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from COVID-19.

Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from COVID-19, a disease caused by the coronavirus SARS-Cov-2. Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from COVID-19.

Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune diseases, chronic inflammatory diseases and inflammatory conditions in connection with infections, including cytokine release syndrome (CRS). Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from conditions as referred to above.

Abstract: A method for manufacturing a pipe conduit arrangement including sticking a pipe stub onto a pipe conduit at least up to the flush state of the of the flange section end-face and the nips conduit end-face, fixing the pipe conduit in the pipe stub in a press fit which is produced by the radial widening of the pipe conduit, and axially clamping the arisen pipe conduit units by way of clamping the flange sections of the pine stubs into the nine conduit arrangement. Also described is a pipe conduit arrangement.